Luminex provides a wide range of solutions such as clinical diagnostics, pharmaceutical drug discovery, and biomedical research. Having a pulse in this field, they quickly sprang into action in early March. In their press release, the company announced updates on the company’s plans, progress, and capabilities to assist laboratories in detecting and diagnosing cases of COVID-19.
“We have been working on multiple solutions to augment our NxTAG and ARIES offerings in order to facilitate and automate the detection of SARS-CoV-2,” said Nachum “Homi” Shamir, President and CEO of Luminex. “These additional alternatives leverage our globally available instrument platforms and assay technologies.”
Click here to learn more about Luminex.